PubRank

J C Glorioso

Author PubWeight™ 199.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cloning of herpes simplex virus type 1 sequences representing the whole genome. J Virol 1981 5.66
2 Transcriptional and genetic analyses of the herpes simplex virus type 1 genome: coordinates 0.29 to 0.45. J Virol 1984 4.09
3 Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001 4.02
4 Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J Virol 1987 3.74
5 High-frequency transfer of cloned herpes simplex virus type 1 sequences to mammalian cells by protoplast fusion. Mol Cell Biol 1981 2.97
6 Physical mapping of the mutation in an antigenic variant of herpes simplex virus type 1 by use of an immunoreactive plaque assay. J Virol 1983 2.96
7 Mutations in herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA. J Virol 1993 2.79
8 Transcriptional control signals of a herpes simplex virus type 1 late (gamma 2) gene lie within bases -34 to +124 relative to the 5' terminus of the mRNA. Mol Cell Biol 1986 2.65
9 The pseudorabies virus gII gene is closely related to the gB glycoprotein gene of herpes simplex virus. J Virol 1987 2.58
10 Rapid identification of nonessential genes of herpes simplex virus type 1 by Tn5 mutagenesis. Science 1987 2.57
11 Expression of herpes simplex virus beta and gamma genes integrated in mammalian cells and their induction by an alpha gene product. Mol Cell Biol 1983 2.15
12 A specific 15-bp TATA box promoter element is required for expression of a herpes simplex virus type 1 late gene. Genes Dev 1988 2.11
13 Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 1998 2.07
14 Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration. J Virol 1988 1.94
15 Immune interactions with cells infected with herpes simplex virus: antibodies to radioiodinated surface antigens. J Immunol 1977 1.94
16 Possible role of Fc receptors on cells infected and transformed by herpesvirus: escape from immune cytolysis. Infect Immun 1978 1.93
17 Method for induction of mutations in physically defined regions of the herpes simplex virus genome. J Virol 1981 1.89
18 A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol 1994 1.86
19 Inversion events in the HSV-1 genome are directly mediated by the viral DNA replication machinery and lack sequence specificity. Cell 1988 1.84
20 Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants. J Virol 1988 1.74
21 Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A 1999 1.68
22 Regulation of the herpes simplex virus type 1 late (gamma 2) glycoprotein C gene: sequences between base pairs -34 to +29 control transient expression and responsiveness to transactivation by the products of the immediate early (alpha) 4 and 0 genes. Nucleic Acids Res 1987 1.68
23 Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993 1.65
24 HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 2005 1.63
25 Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B. J Virol 1993 1.63
26 Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites. J Virol 1985 1.60
27 Identification of mar mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and function in virus penetration. J Virol 1989 1.52
28 Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J Virol 1994 1.51
29 Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Virology 1990 1.49
30 Mutant analysis of herpes simplex virus-induced cell surface antigens: resistance to complement-mediated immune cytolysis. J Virol 1980 1.48
31 Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity. J Virol 1985 1.45
32 HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther 2005 1.42
33 Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 2001 1.41
34 Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production. J Virol 1986 1.39
35 Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992 1.37
36 Effect of cross-immunization on monotypic antibody responses to herpes simplex virus types 1 and 2. J Immunol 1976 1.37
37 Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. J Virol 1995 1.37
38 Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther 2007 1.37
39 Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 1998 1.36
40 Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci 1996 1.35
41 Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. J Gen Virol 1994 1.35
42 Molecular basis of the glycoprotein C-negative phenotypes of herpes simplex virus type 1 mutants selected with a virus-neutralizing monoclonal antibody. J Virol 1986 1.33
43 Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996 1.31
44 A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J Virol 1992 1.29
45 Relationship between expression of herpes simplex virus glycoproteins and susceptibility of target cells to human natural killer activity. J Exp Med 1983 1.27
46 Localization on the herpes simplex virus type 1 genome of a region encoding proteins involved in adsorption to the cellular receptor. J Virol 1990 1.26
47 Microbiological studies on septicemic bullfrogs (Rana catesbeiana). Am J Vet Res 1974 1.26
48 Persistence of herpes simplex virus genes in cells of neuronal origin. J Virol 1980 1.25
49 Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999 1.24
50 Infection by herpes simplex virus and cells of nervous system origin: characterization of a non-permissive interaction. J Gen Virol 1978 1.24
51 Adhesion of type A Pasteurella mulocida to rabbit pharyngeal cells and its possible role in rabbit respiratory tract infections. Infect Immun 1982 1.23
52 The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection. J Virol 1993 1.22
53 Complement-mediated cytolysis of HSV-1 and HSV-2 infected cells: plasma membrane antigens reactive with type-specific and cross-reactive antibody. J Gen Virol 1978 1.21
54 Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J Virol 2000 1.20
55 Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis 1991 1.18
56 Specificity of human natural killer cells in limiting dilution culture for determinants of herpes simplex virus type 1 glycoproteins. J Virol 1986 1.16
57 Pathogenicity in mice of herpes simplex virus type 2 mutants unable to express glycoprotein C. J Virol 1986 1.14
58 Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A 1996 1.12
59 A genetic selection method for the transfer of HSV-1 glycoprotein B mutations from plasmid to the viral genome: preliminary characterization of transdominance and entry kinetics of mutant viruses. Virology 1994 1.12
60 In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther 1992 1.11
61 Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants. J Immunol 1984 1.11
62 Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates. J Virol 1986 1.10
63 Recombinogenic properties of herpes simplex virus type 1 DNA sequences resident in simian virus 40 minichromosomes. J Virol 1990 1.10
64 Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 1998 1.08
65 Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 1997 1.06
66 Detection of herpes simplex virus type 1 latency-associated transcript expression in trigeminal ganglia by in situ reverse transcriptase PCR. J Virol 1996 1.06
67 Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 2006 1.06
68 Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia 2007 1.05
69 Role of interferon in human natural killer activity against target cells infected with HSV-1. J Immunol 1983 1.04
70 Antiviral activity of herpes simplex virus vectors expressing murine alpha 1-interferon. Gene Ther 1995 1.03
71 The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996 1.02
72 Oligomer formation of the gB glycoprotein of herpes simplex virus type 1. J Virol 1991 1.02
73 The carboxy-terminal 41 amino acids of herpes simplex virus type 1 glycoprotein B are not essential for production of infectious virus particles. J Virol 1988 1.01
74 Endogenously produced interferon alpha protects mice from herpes simplex virus type 1 corneal disease. J Gen Virol 1991 1.01
75 Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol 2001 1.01
76 Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2001 0.99
77 Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol 2000 0.98
78 Herpes virus-mediated preproenkephalin gene transfer to the amygdala is antinociceptive. Brain Res 1998 0.97
79 Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 1999 0.97
80 Alterations in the antigenic structure of two major HSV-1 glycoproteins, gC and gB, influence immune regulation and susceptibility to murine herpes keratitis. J Immunol 1989 0.97
81 Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther 2010 0.97
82 Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 2002 0.97
83 Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 1998 0.97
84 In vitro killing of Pasteurella multocida: the effect of rabbit granulocyte and specific antibody source. Am J Vet Res 1979 0.96
85 Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther 2003 0.95
86 Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol 1999 0.95
87 Demonstration and mapping of highly carbohydrate-dependent epitopes in the herpes simplex virus type 1-specified glycoprotein C. J Gen Virol 1987 0.94
88 Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther 1997 0.94
89 Mutational analysis of the major heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C. J Gen Virol 2001 0.94
90 Pathogenicity of glycoprotein C negative mutants of herpes simplex virus type 1 for the mouse central nervous system. Virus Res 1988 0.93
91 Involvement of a high-mobility-group protein in the transcriptional activity of herpes simplex virus latency-active promoter 2. Mol Cell Biol 1996 0.93
92 Gene transfer of p53 to arthritic joints stimulates synovial apoptosis and inhibits inflammation. Mol Ther 2001 0.93
93 Gene therapy progress and prospects: Parkinson's disease. Gene Ther 2003 0.93
94 Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000 0.92
95 Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C. J Virol 1993 0.92
96 Strain differences in the susceptibility and resistance of Pasteurella multocida to phagocytosis and killing by rabbit polymorphonuclear neutrophils. Am J Vet Res 1984 0.92
97 Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci U S A 1999 0.92
98 Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther 2009 0.91
99 Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000 0.91
100 Biochemical characterization of peptides from herpes simplex virus glycoprotein gC: loss of CNBr fragments from the carboxy terminus of truncated, secreted gC molecules. J Virol 1984 0.91
101 Characterization of encephalitis in adult mice induced by intracerebral inoculation of herpes simplex virus type 1 (KOS) and comparison with mutants showing decreased virulence. Lab Invest 1989 0.91
102 Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther 2001 0.91
103 Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther 2007 0.89
104 Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther 2008 0.89
105 Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther 2000 0.89
106 Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther 2000 0.88
107 Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum Gene Ther 2001 0.88
108 Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology 1998 0.88
109 Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther 2007 0.88
110 Genetic analysis of type-specific antigenic determinants of herpes simplex virus glycoprotein C. J Virol 1992 0.88
111 Genetic studies exposing the splicing events involved in herpes simplex virus type 1 latency-associated transcript production during lytic and latent infection. J Virol 1999 0.86
112 Glycoprotein B of herpes simplex virus type 1 oligomerizes through the intermolecular interaction of a 28-amino-acid domain. J Virol 1996 0.86
113 Characterization of the antigenic structure of herpes simplex virus type 1 glycoprotein C through DNA sequence analysis of monoclonal antibody-resistant mutants. J Virol 1990 0.86
114 Pasteurella associated rhinitis of rabbits: efficacy of penicillin therapy. Lab Anim Sci 1981 0.85
115 Engineering herpes simplex virus vectors for gene transfer to neurons. Nat Med 1997 0.85
116 Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B. J Virol 1990 0.84
117 Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 2001 0.83
118 Adenoviral mediated delivery of FAS ligand to arthritic joints causes extensive apoptosis in the synovial lining. J Gene Med 2000 0.83
119 Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression. Proc Natl Acad Sci U S A 1996 0.83
120 Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 1998 0.83
121 cis-acting elements involved in transcriptional regulation of the herpes simplex virus type 1 latency-associated promoter 1 (LAP1) in vitro and in vivo. J Virol 1996 0.83
122 Simple assay for quantitation of Tn5 inversion events in Escherichia coli and use of the assay in determination of plasmid copy number. J Bacteriol 1988 0.83
123 HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain. Gene Ther 2009 0.82
124 Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells. Clin Cancer Res 2000 0.82
125 Resistance of Pasteurella multocida to rabbit neutrophil phagocytosis and killing. Am J Vet Res 1981 0.82
126 Regulation of expression of the glycoprotein genes of herpes simplex virus type 1 (HSV-1). Adv Exp Med Biol 1990 0.82
127 Herpes simplex virus type 1 vector mediated gene transfer to muscle. Gene Ther 1995 0.82
128 Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception. Gene Ther 2012 0.82
129 Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther 2012 0.82
130 Herpes simplex virus type 1 glycoprotein B requires a cysteine residue at position 633 for folding, processing, and incorporation into mature infectious virus particles. J Virol 1998 0.82
131 Herpes simplex virus vectors for gene transfer to the nervous system. J Neurovirol 1997 0.81
132 Design and application of HSV vectors for neuroprotection. Gene Ther 2000 0.81
133 Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo. Gene Ther 1999 0.81
134 Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscul Disord 1998 0.81
135 Development of an HSV-based vector for the treatment of Parkinson's disease. Exp Neurol 1997 0.80
136 Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. J Gene Med 2000 0.80
137 Synovial cell transplants for gene transfer to joints. Transplant Proc 1992 0.80
138 Gene therapy for pain: introduction to the special issue. Gene Ther 2009 0.80
139 Deletion of the S component inverted repeat sequence c' and the nonessential genes U(S)1 through U(S)5 from the herpes simplex virus type 1 genome substantially impairs productive viral infection in cell culture and pathogenesis in the rat central nervous system. J Neurovirol 1997 0.80
140 Cross-linking studies show that herpes simplex virus type 1 glycoprotein C molecules are clustered in the membrane of infected cells. J Gen Virol 1990 0.79
141 Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther 1998 0.79
142 Herpesvirus-mediated systemic delivery of nerve growth factor. Mol Ther 2001 0.79
143 Enzyme-linked immunosorbent assay of serum protein SAA in rhesus monkeys with secondary amyloidosis. Lab Invest 1981 0.79
144 HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther 2000 0.79
145 Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul Disord 1997 0.79
146 LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. Hum Gene Ther 1997 0.79
147 Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Ther 2009 0.78
148 HSV vector-mediated transduction and GDNF secretion from adipose cells. Gene Ther 2005 0.78
149 Stable induction of a 51K cellular protein in neuronal cells surviving herpes simplex virus type 1 infection. Virology 1985 0.78
150 Experimental chronic Pasteurella multocida infection of subcutaneous chambers in the rabbit. Lab Anim Sci 1979 0.78
151 Selective induction of discrete epitopes of herpes simplex virus type 1-specified glycoprotein C by interference with terminal steps in glycosylation. J Gen Virol 1991 0.77
152 Antigenic structure of the herpes simplex virus type 1 glycoprotein C: demonstration of a linear epitope situated in an environment of highly conformation-dependent epitopes. APMIS 1992 0.77
153 Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther 2004 0.77
154 A rapid and sensitive method for plasmid copy number comparisons. Nucleic Acids Res 1989 0.77
155 Laboratory identification of bacterial pathogens of aquatic animals. Am J Vet Res 1974 0.77
156 Activation of human natural killer cells by herpes simplex virus type 1-infected cells. Intervirology 1987 0.77
157 Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy. Gene Ther 2002 0.77
158 Effect of protease inhibitors on yield of HSV-1-based viral vectors. Biotechnol Prog 2000 0.77
159 Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J Neuroimmunol 2000 0.76
160 High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Gynecol Oncol 1998 0.76
161 Targeting gene expression using HSV vectors. Adv Drug Deliv Rev 2001 0.76
162 Purification and structural characterization of herpes simplex virus glycoprotein C. Biochemistry 1987 0.76
163 Serologic type conversion of a herpes simplex virus type 1 (HSV-1) to an HSV-2 epitope caused by a single amino acid substitution in glycoprotein C. J Virol 1990 0.76
164 Regulation of human gene therapy. Science 1995 0.76
165 Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Clin Neurosci 1997 0.76
166 In vivo transgene activation from an HSV-based gene therapy vector by GAL4:vp16. Gene Ther 1996 0.75
167 Information overload? Take the 'Progress and Prospects' cure. Gene Ther 2002 0.75
168 Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy. Biochem Biophys Res Commun 1998 0.75
169 Complement receptors: specific detection by molecular complexes. J Immunol Methods 1978 0.75
170 Herpes simplex virus-enhanced cationic lipid/DNA-mediated transfection. Biotechniques 2000 0.75
171 The frog revisited. Science 1973 0.75
172 A simple method for measuring radioactivity in autoradiograms of polyacrylamide gels. Int J Appl Radiat Isot 1977 0.75
173 Gene therapy approaches for treating rheumatoid arthritis. Clin Orthop Relat Res 2000 0.75
174 I kappa B-mediated apoptotic gene therapy against acute myelogenous leukemia using replication-defective HSV-1 vector expressing TK and mutant I kappa B alpha. Cell Mol Biol (Noisy-le-grand) 2005 0.75
175 Development of replication-defective herpes simplex virus vectors. Methods Mol Med 1997 0.75
176 Non-coding RNAs and the advent of new directions in therapeutics. Gene Ther 2011 0.75
177 Herpes simplex virus-based vectors: problems and some solutions. Adv Neurol 1997 0.75